方法：回顾性分析63例63眼(雷珠单抗治疗组35眼，贝伐珠单抗治疗组28眼)新确诊新生血管年龄相关性黄斑变性患者的资料。治疗12mo后随访，分析比较两组患者的最佳矫正视力(BCVA)和黄斑中心凹厚度(CFT)。采用双尾t检验和单因素方差分析比较两组最佳矫正视力和黄斑中心凹厚度的变化。

结果：雷珠单抗治疗组35眼和贝伐珠单抗治疗组28眼均完成12mo随访，并记录数据。雷珠单抗治疗组最佳矫正视力均值增加0.1logMAR； 相反，贝伐珠单抗治疗组最佳矫正视力均值下降0.06logMAR(P=0.01)。雷珠单抗治疗组13眼(37%)和贝伐珠单抗治疗组4眼(14%)最佳矫正视力至少增加0.3logMAR。雷珠单抗治疗组平均黄斑中心凹厚度减少41.6μm，贝伐珠单抗治疗组减少8.1μm(P=0.003)。两组平均注射次数是4.46次和4.11次(P>0.05)。

结论：玻璃体内注射雷珠单抗组在视力和消水肿方面疗效优于贝伐珠单抗组。但是，两种药的疗效和安全性还需要随机的长期临床试验来验证。

METHODS: A total of 63 eyes(35 eyes treated with ranibizumab and 28 eyes treated with bevacizumab)of 63 patients with newly diagnosed neovascular AMD were analyzed and compared retrospectively. Outcomes included comparison of best-corrected visual acuity(BCVA)and central foveal thickness(CFT)after ranibizumab or bevacizumab treatment at 12mo follow-up. Two-tailed t-tests and one-way ANOVA were used to compare mean changes in BCVA and CFT for different groups.

RESULTS: Thirty-five eyes treated with ranibizumab and 28 eyes treated with bevacizumab were enrolled and completed 12mo follow-up. At 12mo, mean BCVA increased by 0.1logMAR with ranibizumab treatment; however BCVA decreased by 0.06logMAR with bevacizumab treatment(P=0.01). A gain of at least 0.3logMAR in BCVA was observed in 13 eyes(37%)treated with ranibizumab and in 4 eyes(14%)treated with bevacizumab. Mean CFT reduced by 41.6μm and 8.1μm in the ranibizumab and bevacizumab groups, respectively(P=0.003). The mean number of injections per eye was 4.46 with ranibizumab and 4.11 with bevacizumab(P>0.05).

CONCLUSION: Intravitreal ranibizumab yielded better visual and anatomical results than bevacizumab. However, randomized long-term clinical trials are needed to draw conclusions about efficacy and safety of the two drugs.